Clinical data | |
---|---|
Other names | BMS-986205; ONO 7701 |
Routes of administration | Oral |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
DrugBank | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C24H24ClFN2O |
Molar mass | 410.92 g·mol−1 |
3D model ( JSmol) | |
| |
|
Linrodostat (development code BMS-986205) is an experimental drug being studied for its immunomodulating and antineoplastic activities. [1]
Linrodostat is an inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1). [2] [3]
Linrodostat has entered clinical trials for a variety of cancer types including bladder cancer, head and neck cancer, endometrial cancer, gastric cancer, malignant melanoma, liver cancer, non-small cell lung cancer, and solid tumors. [4]
Clinical data | |
---|---|
Other names | BMS-986205; ONO 7701 |
Routes of administration | Oral |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
DrugBank | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C24H24ClFN2O |
Molar mass | 410.92 g·mol−1 |
3D model ( JSmol) | |
| |
|
Linrodostat (development code BMS-986205) is an experimental drug being studied for its immunomodulating and antineoplastic activities. [1]
Linrodostat is an inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1). [2] [3]
Linrodostat has entered clinical trials for a variety of cancer types including bladder cancer, head and neck cancer, endometrial cancer, gastric cancer, malignant melanoma, liver cancer, non-small cell lung cancer, and solid tumors. [4]